Non-invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response.
hepatic venous pressure gradient
machine learning
predictive analysis
proteomics
sustained virologic response
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
02
06
2023
received:
23
01
2023
accepted:
12
06
2023
medline:
14
8
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
ppublish
Résumé
A reduction in hepatic venous pressure gradient (HVPG) is the most accurate marker for assessing the severity of portal hypertension and the effectiveness of intervention treatments. This study aimed to evaluate the prognostic potential of blood-based proteomic biomarkers in predicting HVPG response amongst cirrhotic patients with portal hypertension due to Hepatitis C virus (HCV) and had achieved sustained virologic response (SVR). The study comprised 59 patients from two cohorts. Patients underwent paired HVPG (pretreatment and after SVR), liver stiffness (LSM), and enhanced liver fibrosis scores (ELF) measurements, as well as proteomics-based profiling on serum samples using SomaScan® at baseline (BL) and after SVR (EOS). Machine learning with feature selection (Caret, Random Forest and RPART) methods were performed to determine the proteins capable of classifying HVPG responders. Model performance was evaluated using AUROC (pROC R package). Patients were stratified by a change in HVPG (EOS vs. BL) into responders (greater than 20% decline in HVPG from BL, or <10 mmHg at EOS with >10 mmHg at BL) and non-responders. LSM and ELF decreased markedly after SVR but did not correlate with HVPG response. SomaScan (SomaLogic, Inc., Boulder, CO) analysis revealed a substantial shift in the peripheral proteome composition, reflected by 82 significantly differentially abundant proteins. Twelve proteins accurately distinguished responders from non-responders, with an AUROC of .86, sensitivity of 83%, specificity of 83%, accuracy of 83%, PPV of 83%, and NPV of 83%. A combined non-invasive soluble protein signature was identified, capable of accurately predicting HVPG response in HCV liver cirrhosis patients after achieving SVR.
Sections du résumé
BACKGROUND AND AIMS
A reduction in hepatic venous pressure gradient (HVPG) is the most accurate marker for assessing the severity of portal hypertension and the effectiveness of intervention treatments. This study aimed to evaluate the prognostic potential of blood-based proteomic biomarkers in predicting HVPG response amongst cirrhotic patients with portal hypertension due to Hepatitis C virus (HCV) and had achieved sustained virologic response (SVR).
METHODS
The study comprised 59 patients from two cohorts. Patients underwent paired HVPG (pretreatment and after SVR), liver stiffness (LSM), and enhanced liver fibrosis scores (ELF) measurements, as well as proteomics-based profiling on serum samples using SomaScan® at baseline (BL) and after SVR (EOS). Machine learning with feature selection (Caret, Random Forest and RPART) methods were performed to determine the proteins capable of classifying HVPG responders. Model performance was evaluated using AUROC (pROC R package).
RESULTS
Patients were stratified by a change in HVPG (EOS vs. BL) into responders (greater than 20% decline in HVPG from BL, or <10 mmHg at EOS with >10 mmHg at BL) and non-responders. LSM and ELF decreased markedly after SVR but did not correlate with HVPG response. SomaScan (SomaLogic, Inc., Boulder, CO) analysis revealed a substantial shift in the peripheral proteome composition, reflected by 82 significantly differentially abundant proteins. Twelve proteins accurately distinguished responders from non-responders, with an AUROC of .86, sensitivity of 83%, specificity of 83%, accuracy of 83%, PPV of 83%, and NPV of 83%.
CONCLUSIONS
A combined non-invasive soluble protein signature was identified, capable of accurately predicting HVPG response in HCV liver cirrhosis patients after achieving SVR.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1984-1994Informations de copyright
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-851. doi:10.1016/S0140-6736(08)60383-9
Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749-1761. doi:10.1016/S0140-6736(14)60121-5
Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481-488. doi:10.1053/j.gastro.2007.05.024
Mauro E, Crespo G, Montironi C, et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology. 2018;67(5):1683-1694. doi:10.1002/hep.29557
Sanyal AJ, Harrison SA, Ratziu V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology. 2019;70(6):1913-1927. doi:10.1002/hep.30664
Schwabl P, Mandorfer M, Steiner S, et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 2017;45(1):139-149. doi:10.1111/apt.13844
Mandorfer M, Kozbial K, Schwabl P, et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology. 2020;71(3):1023-1036. doi:10.1002/hep.30885
Castéra L, le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009;50(1):59-68. doi:10.1016/j.jhep.2008.08.018
Tana MM, Muir AJ. Diagnosing liver fibrosis and cirrhosis: serum, imaging, or tissue? Clin Gastroenterol Hepatol. 2018;16(1):16-18. doi:10.1016/j.cgh.2017.06.050
Semmler G, Lens S, Meyer EL, et al. Non-invasive tests for clinically significant portal hypertension after HCV cure. J Hepatol. 2022;77:1573-1585. doi:10.1016/j.jhep.2022.08.025
Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One. 2010;5(12):e15004. doi:10.1371/journal.pone.0015004
Begic E, Hadzidedic S, Kulaglic A, Ramic-Brkic B, Begic Z, Causevic M. SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer's dementia patients. PLoS One. 2019;14(2):e0212261. doi:10.1371/journal.pone.0212261
Ko D, Benson MD, Ngo D, et al. Proteomics profiling and risk of new-onset atrial fibrillation: Framingham heart study. J Am Heart Assoc. 2019;8(6):e010976. doi:10.1161/JAHA.118.010976
Wood GC, Chu X, Argyropoulos G, et al. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep. 2017;7(1):43238. doi:10.1038/srep43238
Corey KE, Pitts R, Lai M, et al. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD. J Hepatol. 2022;76(1):25-33. doi:10.1016/j.jhep.2021.09.026
Abraldes JG, Sarlieve P, Tandon P. Measurement of portal pressure. Clin Liver Dis. 2014;18(4):779-792. doi:10.1016/j.cld.2014.07.002
la Mura V. Cirrhosis and portal hypertension: the importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol. 2015;7(4):688-695. doi:10.4254/wjh.v7.i4.688
de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743-752. doi:10.1016/j.jhep.2015.05.022
Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013;144(1):102-111.e1. doi:10.1053/j.gastro.2012.10.001
Davies DR, Gelinas AD, Zhang C, et al. Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc Natl Acad Sci. 2012;109(49):19971-19976. doi:10.1073/pnas.1213933109
Candia J, Cheung F, Kotliarov Y, et al. Assessment of variability in the SOMAscan assay. Sci Rep. 2017;7(1):14248. doi:10.1038/s41598-017-14755-5
Kraemer S, Vaught JD, Bock C, et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS One. 2011;6(10):e26332. doi:10.1371/journal.pone.0026332
Jacob J, Ngo D, Finkel N, et al. Application of large-scale aptamer-based proteomic profiling to planned myocardial infarctions. Circulation. 2018;137(12):1270-1277. doi:10.1161/CIRCULATIONAHA.117.029443
Emilsson V, Ilkov M, Lamb JR, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science. 2018;361(6404):769-773. doi:10.1126/science.aaq1327
Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3(1):1-25. doi:10.2202/1544-6115.1027
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2021. Accessed December 15, 2021. https://www.R-project.org
Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8), 1-28. doi:10.18637/jss.v042.i08
Camma C, Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Des. 2004;10(17):2123-2130. doi:10.2174/1381612043384321
Myers RP, Regimbeau C, Thevenot T, et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev. 2001;2001(4):CD000369. doi:10.1002/14651858.CD000369
Rout G, Nayak B, Patel AH, et al. Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography. J Clin Exp Hepatol. 2019;9(2):207-214. doi:10.1016/j.jceh.2018.06.009
Kawaguchi T, Ide T, Amano K, et al. Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication. Mol Clin Oncol. 2021;15(4):215. doi:10.3892/mco.2021.2377
Lens S, Alvarado-Tapias E, Mariño Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology. 2017;153(5):1273-1283.e1. doi:10.1053/j.gastro.2017.07.016
Manolakopoulos S, Triantos C, Theodoropoulos J, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol. 2009;51(3):468-474. doi:10.1016/j.jhep.2009.05.031
Vorobioff J, Groszmann R, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996;111(3):701-709. doi:10.1053/gast.1996.v111.pm8780575
Afdhal N, Everson GT, Calleja JL, et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017;24(10):823-831. doi:10.1111/jvh.12706
The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER CC and CC cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65(4):734-740. doi:10.1016/j.jhep.2016.05.045
Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727-733. doi:10.1016/j.jhep.2016.06.015
Mandorfer M, Hernández-Gea V, García-Pagán JC, Reiberger T. Noninvasive diagnostics for portal hypertension: a comprehensive review. Semin Liver Dis. 2020;40(a3):240-255. doi:10.1055/s-0040-1708806
Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology. 2019;70(5):1521-1530. doi:10.1002/hep.30842
Kumar A, Maruyama H, Arora A, et al. Diagnostic accuracy of transient elastography in diagnosing clinically significant portal hypertension in patients with chronic liver disease: a systematic review and meta-analysis. J Med Ultrason. 2022;49(3):333-346. doi:10.1007/s10396-022-01239-x
Zhang R, Chen J, Liu D, Wang Y. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats. Front Med. 2019;13(3):398-408. doi:10.1007/s11684-019-0689-5
Reverter E, Lozano JJ, Alonso C, et al. Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. Liver Int. 2019;39(4):705-713. doi:10.1111/liv.14042